Regulus Therapeutics Inc (NASDAQ:RGLS) – Analysts at Wedbush lowered their Q1 2018 earnings per share estimates for shares of Regulus Therapeutics in a research report issued to clients and investors on Monday. Wedbush analyst L. Moussatos now forecasts that the biopharmaceutical company will post earnings per share of ($0.13) for the quarter, down from their previous estimate of ($0.12). Wedbush has a “Outperform” rating and a $4.00 price target on the stock. Wedbush also issued estimates for Regulus Therapeutics’ Q2 2018 earnings at ($0.13) EPS, Q3 2018 earnings at ($0.13) EPS, Q4 2018 earnings at ($0.13) EPS, FY2018 earnings at ($0.51) EPS, FY2019 earnings at ($0.55) EPS, FY2020 earnings at ($0.64) EPS, FY2021 earnings at ($0.59) EPS and FY2022 earnings at ($0.14) EPS.
Several other research firms have also weighed in on RGLS. Chardan Capital reaffirmed a “neutral” rating on shares of Regulus Therapeutics in a report on Tuesday, January 16th. Zacks Investment Research raised shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 target price for the company in a report on Wednesday, January 24th. Leerink Swann assumed coverage on shares of Regulus Therapeutics in a report on Friday, January 5th. They set an “outperform” rating and a $2.00 target price for the company. Finally, BMO Capital Markets set a $1.00 target price on shares of Regulus Therapeutics and gave the company a “hold” rating in a report on Thursday, March 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and a consensus price target of $2.20.
Regulus Therapeutics (NASDAQ:RGLS) last posted its earnings results on Wednesday, March 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.03. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.02 million. Regulus Therapeutics had a negative net margin of 99,868.07% and a negative return on equity of 201.84%.
Several large investors have recently bought and sold shares of RGLS. Goldman Sachs Group Inc. increased its holdings in shares of Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after purchasing an additional 240,890 shares in the last quarter. Royal Bank of Canada grew its stake in Regulus Therapeutics by 12.1% in the 2nd quarter. Royal Bank of Canada now owns 184,040 shares of the biopharmaceutical company’s stock valued at $182,000 after acquiring an additional 19,934 shares during the period. Victory Capital Management Inc. acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at $347,000. Candriam Luxembourg S.C.A. acquired a new stake in Regulus Therapeutics in the 3rd quarter valued at $750,000. Finally, South Dakota Investment Council grew its stake in Regulus Therapeutics by 37.1% in the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after acquiring an additional 492,969 shares during the period. 53.72% of the stock is owned by hedge funds and other institutional investors.
ILLEGAL ACTIVITY NOTICE: This piece was first published by Week Herald and is the property of of Week Herald. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this piece can be read at https://weekherald.com/2018/03/15/wedbush-analysts-lower-earnings-estimates-for-regulus-therapeutics-inc-rgls.html.
Regulus Therapeutics Company Profile
Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.
Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.